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Multiple myeloma (MM) is characterized by an accumulation of abnormal clonal plasma cells in the bone
marrow. Despite recent advancements in anti-myeloma therapies, MM remains an incurable disease.
Antioxidant molecules are upregulated in many cancers, correlating with tumor proliferation, survival,
and chemoresistance and therefore, have been suggested as potential therapeutic targets. This study
investigated the cross-talk between two antioxidant molecules, thioredoxin reductase (TrxR) and heme
oxygenase-1 (HO-1), and their therapeutic implications in MM. We found that although auranoﬁn, a TrxR
inhibitor, signiﬁcantly inhibited TrxR activity by more than 50% at lower concentrations, myeloma cell
proliferation was only inhibited at higher concentrations of auranoﬁn. Inhibition of TrxR using lower
auranoﬁn concentrations induced HO-1 protein expression in myeloma cells. Using a sub-lethal con-
centration of auranoﬁn to inhibit TrxR activity in conjunction with HO-1 inhibition signiﬁcantly de-
creased myeloma cell growth and induced apoptosis. TrxR was shown to regulate HO-1 via the Nrf2
signaling pathway in a ROS-dependent manner. Increased HO-1 mRNA levels were observed in borte-
zomib-resistant myeloma cells compared to parent cells and HO-1 inhibition restored the sensitivity to
bortezomib in bortezomib-resistant myeloma cells. These ﬁndings indicate that concurrent inhibition of
HO-1 with either a TrxR inhibitor or with bortezomib would improve therapeutic outcomes in MM
patients. Hence, our ﬁndings further support the need to target multiple antioxidant systems alone or in
combination with other therapeutics to improve therapeutic outcomes in MM patients.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple myeloma (MM) is a malignant neoplasm of plasma
cells characterized by an aberrant accumulation of plasma cells in
the bone marrow (BM). In recent years, new therapeutics includ-
ing proteasome inhibitors, bortezomib [1] and carﬁlzomib [2], and
immunomodulatory drugs thalidomide [3] and lenalidomide [4]
signiﬁcantly improve MM patient outcome. Despite such devel-
opments in MM treatment, relapse is inevitable, and MM remainsB.V. This is an open access article u
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nissen).an incurable disease with the median survival rate of 3–5 years.
Thus, better understanding of the myeloma biology and the me-
chanisms underlying chemoresistance can help to develop new
therapeutic modalities with the potential to cure MM.
Heme oxygenase-1 (HO-1) is a cytoprotective enzyme catalyz-
ing the conversion of intracellular heme into biliverdin, free iron,
and carbon monoxide [5]. Biliverdin reductase further reduces
biliverdin into a potent antioxidant bilirubin [6,7], which possesses
anti-inﬂammatory, anti-oxidative, and anti-apoptosis properties
[8,9]. Elevated HO-1 expression and activity have been observed in
various cancer types including renal cell carcinoma [10], prostate
cancer [11], lymphosarcoma [12], melanoma [13], chronic myeloid
leukemia (CML) [14], and chronic lymphocytic leukemia (CLL) [15].
Moreover, HO-1 expression has been shown to increase in re-
sponse to the treatment with chemotherapeutic agents in acute
myeloid leukemia (AML) [16], CML [17], pancreatic cancer [11], and
MM [18]. Inhibition of upregulated HO-1 has been demonstrated
to reverse the chemoresistance and resensitizes cancer cells to the
chemotherapeutic agents in many human cancer types [11,16,17].
Thus, HO-1 serves as a potential therapeutic target in cancer eithernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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agents. Although bortezomib treatment increased HO-1 mRNA
levels in MM [18], the functional role of HO-1 in myeloma cell
survival, growth, and bortezomib resistance has not been estab-
lished. The expression of HO-1 is regulated by many transcription
factors including nuclear factor-кβ (NF-кβ) [19,20], NF-E2-related
factor 2 (Nrf2) [21], activator protein-1 (AP-1) [22], and Bach-1
[23]. However, how HO-1 is regulated in myeloma cells is unclear.
The thioredoxin (Trx) system is one of the major cellular anti-
oxidant systems and is comprised of thioredoxin (Trx), thioredoxin
reductase (TrxR), and NADPH [24]. Both Trx1 and TrxR1 have been
shown to be upregulated in many human cancer types including
MM, and correlated with cancer cell survival, growth, resistance to
apoptosis, and drug resistance [25,26]. Although the Trx system is
a major antioxidant system involved in multiple redox-regulated
signaling pathways in cancer [27,28], it also interacts with other
antioxidant systems. Upon the loss of one antioxidant system, the
cell may activate another antioxidant or stress molecule to com-
pensate for the loss and protect themselves against increased
oxidative stress and chemotherapeutic drugs [29–31]. Several lines
of evidence indicate the involvement of the Trx/TrxR system in the
regulation of HO-1 expression [31–33]. Inhibition of TrxR using
pharmacological inhibitors, such as aurothioglucose, induces HO-1
expression and activity. Moreover, TrxR inhibition using auranoﬁn
has also increased HO-1 expression in an oxidative stress-depen-
dent manner in CLL cells [34]. However, the role of TrxR in reg-
ulating HO-1 and the therapeutic implications of targeting both
TrxR and HO-1 together in MM remains unclear.
The present study was designed to study the cross-talk be-
tween the two antioxidants, TrxR and HO-1 in MM, and the
therapeutic implication of targeting both in conjunction in mye-
loma cells. Our results show that TrxR inhibition induces HO-1
expression through the Nrf2 signaling pathway. We show that HO-
1 inhibition using a pharmacological inhibitor, Zinc Proto-
porphyrin IX (ZnPP IX), sensitizes myeloma cells to undergo
apoptosis in response to TrxR inhibition at the lower concentra-
tions of auranoﬁn. Thus, HO-1 acts as a secondary anti-apoptotic
mechanism and is upregulated to compensate for the loss of TrxR
functions. Our data also show that HO-1 expression is increased in
bortezomib-resistant myeloma cells and its inhibition restores the
sensitivity to bortezomib. These ﬁndings suggest concurrent in-
hibition of HO-1 with either a TrxR inhibitor or with bortezomib
would improve therapeutic outcomes in MM patients.2. Materials and methods
2.1. Cells and reagents
The standard human myeloma cell lines (RPMI8226, U266, and
OPM2) were obtained from Dr. Slavica Vuckovic (QIMR Berghofer
Medical Research Institute). RPMI8226 cells were originally de-
rived from the peripheral blood of a 61-year-old male with mul-
tiple myeloma (IgG lambda-type) [35]. U266 cells were originally
derived from the peripheral blood of a 53-year-old male with IgE-
secreting myeloma (refractory) [36]. OPM2 cells were originally
derived from the peripheral blood of 56-year-old woman with
multiple myeloma in leukemic phase (relapse) [37]. Human per-
ipheral blood mononuclear cells (PBMCs) were isolated from the
whole blood of healthy volunteers and were collected under the
ethical approval BPS/08/14/HREC. Cells were cultured in RPMI-
1640 medium (Gibco) containing 10% (v/v) fetal bovine serum
(FBS) (Bovagen), 200 mM L-glutamine, and 100 U/ml penicillin and
100 mg/ml streptomycin (Invitrogen). The monoclonal anti-HO-1
antibody was purchased from R & D Systems. The monoclonal
anti-Nrf2 antibody, anti-Lamin B1, and anti-β-tubulin antibodieswere purchased from Abcam. The monoclonal anti-HIF-1β anti-
body was purchased from BD Biosciences. The TrxR1 inhibitor
auranoﬁn was purchased from Sigma. An HO-1 inhibitor ZnPP IX
and its control compound CuPP IX were purchased from Enzo Life
Sciences. The dominant negative-Nrf2 plasmid was kindly pro-
vided by Dr. Xilin Chen (Atherogenics, USA) [38].
2.2. TrxR activity assay
RPMI8226, U266, and OPM2 cells were treated with auranoﬁn
(0–2 mM) for 24 h in 6-wells plate. The TrxR activity assays were
performed as described previously [39]. Brieﬂy, treated and un-
treated cells were lysed using 0.5% (v/v) Nonidet P-40 cell lysis
buffer (150 mM NaCl, 50 mM Tris–Cl, pH 8; 0.5% (v/v) Nonidet
P-50, 0.5 mM EDTA, 2 mM PMSF, 1 ml/ml protease inhibitor cocktail
VI, 1 PBS). To omit non-TrxR1-speciﬁc DTNB reduction, cell ly-
sates were treated with or without 8 mM auranoﬁn for 30 min at
room temperature. The TrxR activity was measured using a buffer
containing 0.5 M potassium phosphate, 200 mM EDTA, 20 mM
NADPH, and 125 mM DTNB. TNB production was measured by
following an increase in absorbance at 412 nm for 10 min. The
reaction rates obtained in the presence of auranoﬁn were sub-
tracted from the reaction rates obtained in the absence of aur-
anoﬁn to give the ﬁnal corrected TrxR rates. Units of TrxR activity
(mmoles of TNB produced/minute) were calculated using an ex-
tinction coefﬁcient of 13.6103 M1 of TNB at 412 nm. The spe-
ciﬁc thioredoxin reductase activity was determined using the fol-
lowing equation: Speciﬁc activity (U/mg)¼U/total protein.
2.3. Cell proliferation assay
0.5106 cells were treated with the appropriate drugs for in-
dicated period of time in 24-wells plate. Relative cell proliferation
was assayed using the CellTiter-Blue Cell Viability Assay (Prome-
ga), as per the manufacturer's instructions.
2.4. Western blot analysis
Whole cell extracts were prepared using 0.5% (v/v) Nonidet
P-40 cell lysis buffer. Nuclear and cytosolic fractions were prepared
using Nuclear Protein Extraction Kit (Cayman Chemicals) accord-
ing to the manufacturer's guidelines. Western immunoblotting
analysis was performed as described previously [40]. Blots were
probed with various speciﬁc antibodies (HO-1, Nrf2, Lamin B1, HIF-
1β, and β-tubulin) and ECL detection was done using GE ECL
Western Blotting Substrate (GE Healthcare).
2.5. Caspase-3 activity assay
0.5106 cells were treated with the appropriate drugs for in-
dicated period of time in 24-wells plate. Caspase-3 activity within
the treated and untreated myeloma cell lines and PBMCs was
determined as described previously following the cleavage of Ac-
DEVD-AMC (Enzo Life Sciences, NY, USA), a caspase-3 substrate
[26]. Brieﬂy, treated or untreated cells (0.5106 cells) were pel-
leted, washed with PBS, re-suspended in 10–15 ml of PBS, and
transferred to black-walled 96-wells plate. 90 ml of caspase assay
buffer (5 mM dithiothreitol, 100 mM HEPES, 10% (w/v) sucrose,
0.1% NP-40 at pH 7.25) containing 50 μM Ac-DEVD-AMC was ad-
ded to the samples and the amount of AMC cleaved by caspase-3
was measured at 37 °C by measuring the ﬂuorescence at excitation
wavelength of 370 nm and emission of 445 nm using SpectraMax
plate reader.
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A dicholoroﬂuorescein (DCF) assay was used to determine
cellular ROS generation in myeloma cells and control PBMCs as
described previously [26]. Brieﬂy, 1106 of treated or untreated
cells were washed with PBS and incubated with 10 mM H2DCFDA
(Molecular probes, CA, USA), a redox sensitive cell permeable dye,
for 15 min. Cells were then transferred to black-walled clear-bot-
tom 96-wells plate in triplicate and assessed for H2DCFDA oxida-
tion using a SpectraMax ﬂuorescence plate reader (MolecularFig. 1. Auranoﬁn inhibits TrxR activity in myeloma cells. MM cell lines (RPMI8226, U266
24 h. (A–C) Protein was extracted and TrxR activity was analyzed by measuring the N
protein concentration in RPMI8226 (A), U266 (B), and OPM2 (C). (D–F) Cell proliferatio
Values indicate mean7SEM of three independent experiments performed in triplicate.
pared to the 0 mM auranoﬁn treatment).Devices). Data were analyzed using SoftMax Pro software (Bio-
strategy). The ﬂuorescence intensity measuring the oxidation of
H2DCFDA by ROS represents the amount of intracellular ROS
generation.
2.7. Transient transfections
Cells (2106 per well) were transfected using Amaxa Nucleo-
fector (T-001 program) using 2 ug of empty vector, pcDNA 3.1, and
dominant negative-Nrf2 plasmids. Transfected cells were, and OPM2) were treated with indicated concentrations of auranoﬁn (0–2 mM) for
ADPH-dependent reduction of DTNB by TrxR enzyme and normalized against the
n was assessed by CellTiter Blue assay in RPMI8226 (D), U266 (E), and OPM2 (F).
One-way ANOVA followed by Tukey's post-test was employed. *Po0.0001 (com-
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2.8. RNA extraction and quantitative real time-PCR
Total RNA was extracted from parent U266 and bortezomib-re-
sistant (U266-BR) cells (1106 cells) using TRIsureTM Lysis solution
(Bioline) according to the manufacturer's instructions. Total RNA was
reverse transcribed using the SensiFASTTM cDNA synthesis kit (Bio-
line). Resultant cDNA was analyzed by real-time quantitative PCR
(RT-qPCR) using SensiFASTTM SYBRs No-Rox Kit (Bioline) and RT-
qPCR primers for L32 [forward 5′-CAGGGTTCGTAGAAGATTCAAGGG-
3′ and reverse 5′-CTTGGAGGAAAACATTGTGAGCGATC-3′] [41] and
HO-1 [forward 5′-GCAGTCAGGCAGAGGGTGATAGAA-3′ and reverse
5′-GGGCTCTGGTCCTTGGTGTCAT-3′] (Integrated DNA Technologies,
IA, ISA), on the QuantStudios 6 Flex Real-Time PCR System (Applied
Biosystems) according to the manufacturer's guidelines. Reaction
conditions were 95 °C for 5 s, 60 °C for 10 s, and 72 °C for 20 s. The
comparative cycle threshold algorithm (ΔΔCt) method was used to
analyze gene expression. The mRNA was normalized against L32
expression [41].
2.9. Statistical analysis
Data were analyzed by using the software GraphPad Prism 6
(GraphPad Software). Values are presented as mean7SEM. Sta-
tistical signiﬁcance was determined by the speciﬁed statistical test.
Po0.05 was considered signiﬁcant.Fig. 2. TrxR inhibition induces HO-1 expression in myeloma cells. (A) Expression of
HO-1 in myeloma patient cells (new MM and relapsed) and in normal cells were
determined from the gene expression proﬁle arrays deposited in the gene ex-
pression omnibus database (GSE6477). One-way ANOVA followed by Tukey's post-
test were employed. Po0.05 (compared to the normal cells) (B–E) Myeloma cell
lines RPMI8226 (B), U266 (C), OPM2 (D), and control PBMCs (E) were treated with
indicated concentrations of auranoﬁn (AF) (0–2 mM) for 24 h. Whole cell extracts
were prepared, and HO-1 protein expressionwas analyzed by western blot analysis.
β-tubulin was used as a loading. Western blots are representative of three in-
dependent experiments.3. Results
3.1. Auranoﬁn inhibits TrxR activity in myeloma cells
We have previously shown that TrxR1 is upregulated in mye-
loma cells and auranoﬁn, a TrxR inhibitor, induces myeloma cell
death [26]. Here, we aimed to correlate auranoﬁn-induced in-
hibition of TrxR activity with myeloma cell death and to study the
interactions of TrxR with other antioxidants. Results showed that
auranoﬁn signiﬁcantly inhibited TrxR activity in all three myeloma
cell lines (RPMI8226, U266, and OPM2) and the IC50 value was
achieved at 0.48 mM, 0.46 mM, and 0.457 mM in RPMI8226, U266,
and OPM2 cells, respectively (Fig. 1A–C). Interestingly, these aur-
anoﬁn concentrations were not sufﬁcient to reduce cell prolifera-
tion and higher auranoﬁn concentrations were required to sig-
niﬁcantly reduce cell proliferation in all three myeloma cell lines
(Fig. 1D–F). We previously showed that auranoﬁn treatment did
not exert any signiﬁcant cytotoxic effect on control peripheral
blood mononuclear cells (PBMCs) [26].
3.2. TrxR inhibition induces HO-1 expression on myeloma cells
Based on the observed discrepancy in Auranoﬁn concentrations
required for inhibition of TrxR and cell proliferation, we hy-
pothesized that TrxR inhibition may activate another antioxidant
molecule, which may serve as a secondary anti-apoptotic me-
chanism in myeloma cells. Firstly, by using a publicly available
gene expression database (GSE6477), we showed that HO-1 ex-
pression is signiﬁcantly lower in new and relapsed MM patients
compared to healthy individuals (Fig. 2A). Studies have shown that
TrxR inhibition induces hepatic HO-1 expression [31]. Therefore,
we investigated the effect of TrxR inhibition on HO-1 expression in
myeloma cells and control PBMCs. Western blot results showed a
marked induction of HO-1 expression when TrxR activity was in-
hibited by 50% in all three myeloma cell lines (Fig. 2B–D). How-
ever, auranoﬁn treatment did not induce HO-1 protein expression
in control PBMCs (Fig. 2E). In addition, we also investigatedwhether Trx1 inhibition induces HO-1 expression in myeloma
cells. RPMI8226, U266, and OPM2 cells were treated with a Trx1
inhibitor, PX-12 (0–20 mM), and HO-1 protein expression was
analyzed. Interestingly, targeting Trx1 did not induce HO-1 ex-
pression in myeloma cells at any concentration of PX-12 (data not
shown).
3.3. TrxR and HO-1 inhibition in conjunction induces apoptosis in
myeloma cells
We further analyzed whether increased HO-1 expression in
response to TrxR inhibition can rescue myeloma cells from
Fig. 3. TrxR and HO-1 inhibition in conjunction inhibits myeloma cell proliferation. Myeloma cell lines (RPMI8226, U266) and normal PBMCs were treated with 5 mM ZnPP IX
(a HO-1 inhibitor) (A, C, E, respectively) or its control compound CuPP IX (B, D, F, respectively) alone or in combination with 1 mM auranoﬁn for 24, 48, and 72 h. Cell
proliferation was assessed by CellTiter Blue assay at each time-point. Values indicate mean7SEM of three independent experiments performed in triplicates. Two-way
ANOVA followed by Sidak's post-test were employed. *Po0.05 (compared to the cells treated with auranoﬁn and ZnPP IX alone at each time-point).
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combination with HO-1 can induce myeloma cell death, normal
peripheral blood mononuclear cells (PBMCs), RPMI8226, and U266
cells were treated with 5 mM Zinc Protoporphyrin IX (ZnPP IX) (an
HO-1 inhibitor) or its control compound Copper Protoporphyrin IX
(CuPP IX) and 1 mM auranoﬁn (a concentration that inhibits TrxR
activity by more than 50%) either alone or in combination for 24,
48, and 72 h. To optimize the assays, myeloma cells were treated
with increasing concentrations of ZnPP IX and CuPP IX (0–10 mM)
and a sub-lethal concentration of ZnPP IX, 5 mM, was selected forsubsequent experiments (data not shown). In RPMI8226 cells,
ZnPP IX, CuPP IX, and auranoﬁn alone had little or no effect on the
cell proliferation (Fig. 3A and B). However, in combination with
auranoﬁn ZnPP IX (Fig. 3A), but not CuPP IX (Fig. 3B), signiﬁcantly
reduced RPMI8226 cell proliferation by approximately 35% and
50% after 48 and 72 h treatment, respectively. Similarly, in U266
cells, ZnPP IX, CuPP IX, and auranoﬁn alone had no effect on cell
proliferation (Fig. 3 C and D). However, auranoﬁn and ZnPP IX
(Fig. 3C), but not CuPP IX (Fig. 3D), in combination signiﬁcantly
reduced U266 cell proliferation by approximately 70% after 24 h
Fig. 4. Inhibiting TrxR in combination with HO-1 induces myeloma cell apoptosis.
(A, B) Myeloma cell lines RPMI8226 (A) and U266 (B) were treated with 5 mM ZnPP
IX or its control compound CuPP IX alone or in combination with 1 mM auranoﬁn
for 24 h. Caspase-3 activity in treated and untreated cells was measured by mon-
itoring the cleavage of Ac-DEVD-AMC. Values indicate mean7SEM of three in-
dependent experiments. One-way ANOVA followed by Tukey's post-test was em-
ployed. * (compared to the untreated control cells), Δ (compared to either AF alone
or ZnPP IX alone), Po0.05.
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combination exerted no signiﬁcant cytotoxic effect on normal
PBMCs (Fig. 3E and F).
We next examined the mode of myeloma cell death in response
to TrxR and HO-1 inhibition. RPMI8226 and U266 cells were
treated with 1 mM auranoﬁn and 5 mM ZnPP IX either alone or in
combination for 24 h and caspase-3 activity was measured. Mye-
loma cells were also treated with 5 mM CuPP IX and 1 mM aur-
anoﬁn either alone or in combination as a control for ZnPP IX.
Results showed that auranoﬁn and ZnPP IX co-treatment sig-
niﬁcantly increased caspase-3 activity by 2.2-fold and 2.5-fold in
RPMI8226 (Fig. 4A) and U266 (Fig. 4B) cells, respectively, sug-
gesting that myeloma cells are undergoing apoptosis when TrxR
and HO-1 are co-inhibited. Treatment of myeloma cells with aur-
anoﬁn and CuPP IX together had no effect on caspase-3 activity
(Fig. 4A and B).
3.4. TrxR inhibition induces HO-1 expression in myeloma cells
through Nrf2 activation
Since HO-1 is regulated by multiple transcription factors in-
cluding Nrf2, NF-κβ, and AP-1, we investigated the underlying
molecular mechanism by which TrxR may regulate HO-1 in mye-
loma cells. RPMI8226 and U266 cells were treated with auranoﬁn
(0–2 mM) for 24 h, cytosolic and nuclear fractions were prepared,
and Nrf2 and HO-1 protein expression was analyzed. Western blot
results showed that auranoﬁn-induced TrxR inhibition increasednuclear accumulation of Nrf2 in both RPMI8226 and U266 cells
(Fig. 5A and B). As little as 0.25 mM auranoﬁn increased nuclear
Nrf2 protein levels in both myeloma cell lines (Fig. 5A and B). Nrf2
protein levels were undetectable in the cytosolic fractions in both
cell lines (data not shown). Western blot results also showed that
TrxR inhibition increased HO-1 protein levels in both myeloma cell
lines, which correlated with increased nuclear Nrf2 protein levels.
To conﬁrm the involvement of the Nrf2 pathway in TrxR-
mediated HO-1 regulation in myeloma cells, we inhibited Nrf2
using dominant negative-Nrf2 (dn-Nrf2) [38]. U266 cells were
transfected with dn-Nrf2 for 24 h, subsequently treated with or
without 1 mM auranoﬁn for 24 h, and HO-1 protein expression was
analyzed. Results showed a statistically signiﬁcant decrease in HO-
1 protein levels in dn-Nrf2-transfected U266 cells after auranoﬁn
treatment compared to the control cells (Fig. 5C and D).
3.5. ROS play an important role in TrxR-mediated HO-1 expression
HO-1 has been shown to be involved in the regulation of redox
equilibrium in human cells [42], and it is reported that in-
tracellular ROS levels are increased when TrxR is inhibited [26].
We therefore examined the role of ROS in myeloma cells after TrxR
and HO-1 inhibition. Control PBMCs and U266 cells were treated
with auranoﬁn (1 mM) and ZnPP IX (5 mM) alone or in combination
for 24 h and ROS production and caspase-3 activity were mea-
sured. Results showed that intracellular ROS levels were increased
when TrxR was inhibited (by 1.5-fold compared to untreated
control) and were further increased when HO-1 was co-inhibited
(by 2.2-fold compared to untreated control and 1.5-fold compared
to TrxR inhibition alone) (Fig. 6A). No signiﬁcant increase in in-
tracellular ROS levels was observed when control PBMCs were
treated with either auranoﬁn or ZnPP alone or in combination
(Fig. 6A). A ROS quencher, the antioxidant N-acetylcysteine (NAC),
blocked the apoptotic response by inhibiting caspase-3 activity in
U266 cells with both TrxR and HO-1-inhibited (Fig. 6B). This
suggests that ROS are effectors of apoptosis in myeloma cells when
TrxR and HO-1 are inhibited.
We then analyzed the role of ROS in TrxR-mediated HO-1 ex-
pression in myeloma cells. RPMI8226 and U266 cells were treated
with both auranoﬁn (1 mM) and NAC (5 mM) either alone or in
combination for 24 h, and HO-1 and Nrf2 protein expression were
analyzed. Western blot results showed that auranoﬁn-induced
TrxR inhibition increased nuclear Nrf2 and cytosolic HO-1 protein
levels in both MM cell lines (Fig. 6C). Addition of NAC markedly
decreased both Nrf2 and HO-1 protein levels in the nucleus and
cytosol, respectively, in both myeloma cell lines (Fig. 6C). This
suggests the involvement of ROS in TrxR-mediated HO-1 expres-
sion in myeloma cells.
3.6. HO-1 inhibition overcomes bortezomib resistance in myeloma
cells
To investigate the role of HO-1 in bortezomib resistant mye-
loma cells, we ﬁrst analyzed HO-1 mRNA and protein levels in
previously characterized bortezomib-resistant U266 (U266-BR)
[26] and parent U266 cells. Signiﬁcantly higher HO-1 mRNA levels
were observed in U266-BR cells compared to the parent U266 cells
(Fig. 7A). Western blot results showed that 10 nM bortezomib
treatment induced HO-1 protein expression in U266-BR cells, but
lower concentrations of bortezomib did not induce HO-1 protein
expression (Fig. 7B). To examine whether HO-1 inhibition over-
comes bortezomib resistance in myeloma cells, U266-BR cells
were treated with 10 mM ZnPP IX and 10 nM bortezomib either
alone or in combination for 48 h and cell proliferation was ana-
lyzed. While ZnPP IX and bortezomib alone had no effect on U266-
BR cell proliferation, ZnPP IX and bortezomib in combination
Fig. 5. TrxR inhibition induces HO-1 expression in myeloma cells through Nrf2 activation. (A, B) Myeloma cell lines RPMI8226 (A) and U266 (B) were treated with indicated
concentrations of auranoﬁn (0–2 mM) for 24 h. Nuclear and cytosolic fractions were prepared, and Nrf2 and HO-1 protein expression was analyzed by western blot analysis in
the respective cellular fractions. (C) U266 cells were transfected with pcDNA3.1 empty vector and dominant negative-Nrf2 (dn-Nrf2) using Amaxa Nucleofection Technology
(program T-001). 24 h post-transfection U266 cells were treated with or without 1 mM auranoﬁn for 24 h. Whole cell extracts were prepared and HO-1 protein expression
was analyzed by western blot analysis. Lamin B1 and HIF-1β (nuclear fractions) and β-tubulin (cytosolic and whole cell fractions) were used as loading controls. Western
blots are the representative of three independent experiments. (D) HO-1 protein levels were quantiﬁed by densitometry analysis using Image Gauge V4.0 software.
Quantiﬁcation data are expressed as mean7SEM of three independent experiments. Unpaired student t test was employed. *Po0.05.
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50%. Lower concentrations of ZnPP IX were also tested in combi-
nation with bortezomib (10 nM), but no signiﬁcant effect on cell
proliferation was observed (data not shown).4. Discussion
This study highlights the cross-talk between two antioxidants,
TrxR and HO-1, in myeloma cells. We previously showed thatTrxR1 is upregulated in myeloma cells and its inhibition induced
myeloma cell apoptosis [26]. This study showed that myeloma cell
proliferation was not affected when TrxR activity was inhibited by
more than 50% at lower auranoﬁn concentrations (Fig. 1), sug-
gesting the activation of another antioxidant system, which may
act as a secondary anti-apoptotic mechanism. Previous studies
suggested that glutathione and glutaredoxins systems rescue cells
from apoptosis when TrxR is inhibited either by auranoﬁn or
aurothioglucose [29,30]. Our data showed that inhibition of TrxR
activity by 50% induced HO-1 protein expression in all three
Fig. 6. ROS play an important role in TrxR-mediated HO-1 expression in myeloma cells. (A) Control PBMCs and U266 cells were treated with 1 mM AF and 5 mM ZnPP IX either
alone or in combination for 24 h. Intracellular ROS levels were assessed by measuring the oxidation of H2DCFDA dye. (B) U266 cells were treated with 1 mM AF and 5 mMNAC
either alone or in combination for 24 h. Apoptosis was examined by measuring the caspase-3 activity. One-way ANOVA followed by Tukey's post-test were employed. Values
indicate mean7SEM of three independent experiments performed in triplicates. For caspase-3 activity assay (n¼3). * (compared to untreated control), Δ (compared to AF
treatment alone), Po0.05.
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treatment did not induce HO-1 protein expression in control
PBMCs, suggesting that the effect of TrxR inhibition on HO-1 ex-
pression is speciﬁc to myeloma cells. Thus, inhibition of TrxR ac-
tivity by auranoﬁn induces HO-1 expression in myeloma cells,
which may serve as a secondary anti-apoptotic mechanism in
TrxR-inhibited myeloma cells.
To our knowledge, this is the ﬁrst study to report the ther-
apeutic potential of inhibiting both TrxR and HO-1 together in
cancers. This study highlights the role of HO-1 as a secondary anti-
apoptotic molecule in MM, which only becomes active when the
primary defense mechanism such as TrxR, is inhibited. We showed
that, like AML cells [20], MM patient cells have low HO-1 ex-
pression levels compared to healthy cells (Fig. 2). HO-1 expression
has been shown to increase in AML cells upon treatment with
chemotherapeutic agents such as cytarabine, daunorubicin, and
bortezomib, and its inhibition sensitized AML cells to these drugs
[16,43]. Moreover, arsenic trioxide treatment also increased HO-1
expression in different myeloma cell lines and its inhibition re-
duced myeloma cell proliferation [44]. In AML cells, HO-1 ex-
pression has been shown to increase in response to NF-кβ in-
hibition, and HO-1-inhibited AML cells became more susceptible
to the NF-кβ inhibitor, BAY-11-7082 indicating that HO-1 serves as
a secondary anti-apoptotic mechanism in these cells [20]. Our
results showed that HO-1 inhibition using ZnPP IX (5 mM) in
conjunction with auranoﬁn (1 mM) signiﬁcantly reduced pro-
liferation and induced apoptosis in myeloma cell lines (Figs. 3 and4). However, ZnPP IX (5 mM) and auranoﬁn (1 mM) in combination
had no cytotoxic effect on normal PBMCs suggesting that this
therapeutic combination can be a safe approach to treat MM pa-
tients. These ﬁndings indicate that HO-1 serves as a secondary
anti-apoptotic mechanism in myeloma cells and is upregulated to
compensate for the loss of TrxR functions. Therefore, we suggest
inhibiting HO-1 could potentially enhance the cytotoxic effect of
TrxR inhibitors in myeloma cells with minimal adverse effect on
normal cells. It has been shown that the presence of the HO-1
inhibitor, ZnPP IX, in vivo can enhance tumor responsiveness to
anti-cancer agents [45]. Moreover, another study showed that
TrxR1 knockdown upregulated the glutathione system in mouse
embryonic ﬁbroblasts and concomitant inhibition of TrxR1 and
glutathione signiﬁcantly reduced tumor growth in vivo [46]. Taken
together, we suggest that inhibiting multiple antioxidant systems
in combination may provide more effective therapeutic strategy to
combat cancers including MM.
This study also highlighted a molecular mechanism by which
TrxR inhibition induces HO-1 expression in myeloma cells. An
oxidative stress sensitive transcription factor Nrf2 binds the anti-
oxidant response element (ARE) located in the upstream promoter
region of HO-1 [21]. In this study, we showed that auranoﬁn
treatment increased Nrf2 protein levels in the nucleus and HO-1
protein levels in the cytoplasm of myeloma cells (Fig. 5). Moreover,
Nrf2 inhibition using a dn-Nrf2 expressing plasmid [38] sig-
niﬁcantly decreased HO-1 protein levels in response to TrxR in-
hibition (Fig. 5). Thus, our results indicated that TrxR inhibition
Fig. 7. HO-1 inhibition overcomes bortezomib resistance in myeloma cells. (A) HO-
1 mRNA levels were analyzed in parent U266 and bortezomib-resistant U266
(U266-BR) cells by RT-qPCR and normalized against L32 housekeeping gene. Values
indicated mean7SEM (n¼3). Unpaired student t test was employed. *Po0.05
(B) U266-BR cells were treated with indicated concentrations of bortezomib (Btz)
(0–10 nM) for 24 h, whole cell extracts were prepared, and HO-1 protein expres-
sion was analyzed byWestern blot analysis. β-tubulin was used as a loading control.
Western blots are representative of three independent experiments. (C) U266-BR
cells were treated with 10 mM ZnPP IX and 10 nM Btz either alone or in combina-
tion for 48 h. Cell proliferation was assessed by CellTiter Blue assay. Values in-
dicated mean7SEM of three independent experiments performed in triplicates.
One-way ANOVA followed by Tukey's post-test were employed. *Po0.05 (com-
pared to other treatment groups).
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chinery in myeloma cells.
Our results showed that inhibiting TrxR and HO-1 in conjunc-
tion signiﬁcantly increased intracellular ROS levels and caspase-3
activity (Fig. 6). Addition of NAC decreased caspase-3 activation in
response to TrxR and HO-1 co-inhibition indicating that HO-1
protects myeloma cells from apoptosis upon TrxR inhibition byremoving ROS. Furthermore, we also showed that addition of NAC
has markedly decreased nuclear Nrf2 and cytosolic HO-1 protein
levels (Fig. 6). Thus, ROS plays a key role in TrxR-mediated HO-1
expression in myeloma cells. Previous studies have suggested that
HO-1 protects AML cells from apoptosis in response to treatment
with cytarabine, daunorubicin, and BAY-11-7082 by removing ROS
generated by these drugs [16,20].
In recent years, HO-1 has emerged as an effective drug target to
overcome chemoresistance in many human cancer types. Upre-
gulated enzymatic antioxidant defenses and stress-responsive
proteins have been suggested as potential mechanisms re-
sponsible for drug resistance in cancer cells [47]. The gene ex-
pression proﬁling of docetaxel-resistant breast carcinoma patients
revealed elevated levels of the antioxidant genes including Trx,
glutathione, and peroxiredoxins [48]. Moreover, HO-1 expression
was shown to be increased in recurrent or relapsed prostate can-
cer patients [49]. We and another group showed an increased HO-
1 mRNA levels in bortezomib-resistant myeloma cells [18], how-
ever, the functional role of HO-1 in overcoming bortezomib re-
sistance in myeloma cells is unknown. Bortezomib-resistant
myeloma cells have been shown to have increased Nrf2 mRNA
levels compared to their parent counterpart [50]. Since Nrf2 reg-
ulates HO-1 gene transcription by directly binding to the ARE site
in the HO-1 promoter region [21], elevated Nrf2 levels may be
responsible for the increased HO-1 transcript levels in bortezomib-
resistant myeloma cells. However, the exact molecular mechanism
for the elevated HO-1 mRNA levels in bortezomib-resistant mye-
loma cells warrants further investigation.
This study, for the ﬁrst time, highlights a novel strategy to
overcome bortezomib resistance in MM by inhibiting HO-1. We
showed that bortezomib treatment markedly increased HO-1
protein levels in U266-BR cells. Our data showed that HO-1 in-
hibition using its inhibitor, ZnPP IX, signiﬁcantly restored the
sensitivity to bortezomib in bortezomib-resistant myeloma cells
(Fig. 7). Our data complements other studies where HO-1 inhibi-
tion using speciﬁc siRNA or its inhibitor, ZnPP IX, has been shown
to increase the sensitivity of pancreatic cancer cells, cholangio-
carcinoma cells, AML, and CML to chemo- and radiotherapy
[11,16,17,51]. Thus, inhibition of HO-1 in combination with other
conventional therapies may offer a novel approach to treat bor-
tezomib-resistant relapsed/refractory MM patients.
In conclusion, we report that TrxR inhibition induces HO-1
expression and that inhibiting TrxR and HO-1 together induces
myeloma cell apoptosis. Therefore HO-1 serves as a secondary
anti-apoptotic mechanism in myeloma cells. Our ﬁndings suggest
that HO-1 has a signiﬁcant role in MM; however, this role of HO-1
is only revealed when TrxR activity is inhibited. Our ﬁndings fur-
ther point towards the need of targeting multiple antioxidant
systems to combat MM more effectively.Acknowledgments
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